IRA-PRIME: Efficacy in controlling glycaemia with VictozaÂ® (liraglutide) as add-on to metformin vs. OADs as add-on to metformin after up to 104 weeks of treatment in subjects with type 2 diabetes inadequately controlled with metformin monotherapy and treated in a primary care setting - LIRA-PRIME

ovo Nordisk India Private Ltd0 个研究点目标入组 207 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1. Male or female >= 18 years of age limit of signing informed consent. 2. Subjects diagnosed(clinically) with type 2 diabetes >= 90 days prior to screening visit. 3. Stable daily dose of metformin as a monotherapy >= 1500mg or maximum tolerated dose within 60 days prior to screening visit. 4. HbA1C 7.5-9.0%(59-75mmol/mol)(both inclusive ) and measured within the last 90 days prior to screening visit.

•1. Previous participation in this trial. Participation is defined as signed informed consent.
•2. Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing
•potential and not using adequate contraceptive methods (adequate contraceptive measures as
•required by local regulation or practice).
•3. Receipt of any investigational medicinal product within 30 days before the screening visit.
•4. Treatment with any medication for the indication of diabetes other than metformin in a period of 60 days before the screening visit. An exception is short-term treatment (<=7 days in total) with insulin in connection with intercurrent illness.
•5. Any disorder, which in the investigatorâ??s opinion might jeopardise subjectâ??s safety or
•compliance with the protocol.

发起方

ovo Nordisk India Private Ltd